$PTLA $25.74 Sold most of my remaining tranche to lock in gains as it runs to it's catalyst. PDUFA August 21 under priority review for BLA seeking FDA approval to reverse the blood thinning activity. Still holding a toehold position in case it pulls back and allows for one more run.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.